Literature DB >> 24561423

Successful treatment of refractory adult-onset still disease with canakinumab: a case report.

Simone Barsotti1, Rossella Neri, Valentina Iacopetti, Anna d'Ascanio, Rosaria Talarico, Alessandra Tripoli, Stefano Bombardieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24561423     DOI： 10.1097/RHU.0000000000000082

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN： 1076-1608            Impact factor:   3.517


× No keyword cloud information.
  7 in total

Review 1.  Treatment of systemic-onset juvenile arthritis with canakinumab.

Authors:  Joachim Peitz; Gerd Horneff
Journal:  Open Access Rheumatol       Date:  2015-02-18

2.  Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study.

Authors:  Serena Colafrancesco; Roberta Priori; Guido Valesini; Lorenza Argolini; Elena Baldissera; Elena Bartoloni; Daniele Cammelli; Giovanni Canestrari; Luca Cantarini; Elena Cavallaro; Giulio Cavalli; Lucia Cerrito; Paola Cipriani; Lorenzo Dagna; Ginevra De Marchi; Salvatore De Vita; Giacomo Emmi; Gianfranco Ferraccioli; Micol Frassi; Mauro Galeazzi; Roberto Gerli; Roberto Giacomelli; Elisa Gremese; Florenzo Iannone; Giovanni Lapadula; Giuseppe Lopalco; Raffaele Manna; Alessandro Mathieu; Carlomaurizio Montecucco; Marta Mosca; Ilaria Piazza; Matteo Piga; Irene Pontikaki; Micol Romano; Silvia Rossi; Maurizio Rossini; Piero Ruscitti; Elena Silvestri; Chiara Stagnaro; Rosaria Talarico; Angela Tincani; Ombretta Viapiana; Gianfranco Vitiello; Francesca Fabris; Sara Bindoli; Leonardo Punzi; Paola Galozzi; Paolo Sfriso
Journal:  Front Pharmacol       Date:  2017-06-13       Impact factor: 5.810

3.  Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy.

Authors:  François Vercruysse; Thomas Barnetche; Estibaliz Lazaro; Emilie Shipley; François Lifermann; Alexandre Balageas; Xavier Delbrel; Bruno Fautrel; Christophe Richez; Thierry Schaeverbeke; Marie-Elise Truchetet
Journal:  Arthritis Res Ther       Date:  2019-02-12       Impact factor: 5.156

Review 4.  Mechanisms, biomarkers and targets for adult-onset Still's disease.

Authors:  Eugen Feist; Stéphane Mitrovic; Bruno Fautrel
Journal:  Nat Rev Rheumatol       Date:  2018-10       Impact factor: 20.543

Review 5.  Biological therapy of traditional therapy-resistant adult-onset Still's disease: an evidence-based review.

Authors:  Sha Zhou; Jianjun Qiao; Juan Bai; Yinhua Wu; Hong Fang
Journal:  Ther Clin Risk Manag       Date:  2018-01-24       Impact factor: 2.423

6.  Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease.

Authors:  Paola Galozzi; Chiara Baggio; Sara Bindoli; Francesca Oliviero; Paolo Sfriso
Journal:  Front Pharmacol       Date:  2018-09-21       Impact factor: 5.810

7.  Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.

Authors:  Serena Colafrancesco; Maria Manara; Alessandra Bortoluzzi; Teodora Serban; Gerolamo Bianchi; Luca Cantarini; Francesco Ciccia; Lorenzo Dagna; Marcello Govoni; Carlomaurizio Montecucco; Roberta Priori; Angelo Ravelli; Paolo Sfriso; Luigi Sinigaglia
Journal:  Arthritis Res Ther       Date:  2019-12-11       Impact factor: 5.156
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.